A Phase 2 interventional study of cortexolone 17α-propionate in Acne Vulgaris, sponsored by Intrepid Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-12-02.
Sponsored by Intrepid Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.
Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 2, and was the 2nd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 12–55
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Allied Hospital Faisalabad · Sites in Pakistan
Ages 15+
Khyber Teaching Hospital
Ages 12–35
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Ages 12+
By country, each count listing its studies:
Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 2012; this study’s year is marked. 1 started in 2013.
This study's enrollment of 42 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 50 across the 19 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 8 most frequent:
Intrepid Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Intrepid Therapeutics, Inc. has 2 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies testing clascoterone in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673094Khyber Teaching HospitalComparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris | 2027-02 |
| NCT07883538Pak Emirates Military HospitalComparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris | 2027-04-30 |
| NCT07881315Allied Hospital FaisalabadClascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing clascoterone in Acne Vulgaris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical cream, 1.0% concentration, applied every twelve hours
Drug: cortexolone 17α-propionate
Also known as: CB-03-01, clascoterone (USAN, INN)
Change in HPA Axis Response to Cosyntropin
Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin injection (Cosyntropin Stimulation Test - CST). Prior to CST, a pre-CST blood sample is taken between 7AM to 9AM. Thirty minutes after CST, a post-CST blood sample is collected. HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.
Time frame: Baseline and Day 14
PK Profiles (Cmax) of Cortexolone 17α-propionate
Max concentration (Cmax) of cortexolone 17α-propionate in plasma following the first application (i.e., Day 1, 0-12 hours) and last application (i.e., Day 14, 0-12 hours).
Time frame: Baseline and Day 14
PK Profiles (AUC) of Cortexolone 17α-propionate
Area under the plasma concentration curve (0-12 hours) of cortexolone 17α-propionate at baseline (i.e., Day 1, after first application \[0-12 hours\]) and at Day 14 (i.e., Day 14, after last application \[0-12 hours\]).
Time frame: Baseline and Day 14
PK Profiles (Cavg) of Cortexolone 17α-propionate
Average concentration of cortexolone 17α-propionate in plasma calculated as the ratio of the AUC(0-12 hours) and the dosing interval (i.e., 12 hours) at baseline (i.e., Day 1, after first application) and at Day 14 (after last application).
Time frame: Baseline and Day 14
| Milestone | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) |
|---|---|---|
| Started | 20 | 22 |
| Completed | 20 | 22 |
| Not completed | 0 | 0 |
Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin injection (Cosyntropin Stimulation Test - CST). Prior to CST, a pre-CST blood sample is taken between 7AM to 9AM. Thirty minutes after CST, a post-CST blood sample is collected. HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.
| mcg/dL | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) |
|---|---|---|
| Baseline (pre-CST) | 17.0 ± 5.98 | 16.8 ± 4.71 |
| Baseline (post-CST) | 27.7 ± 3.43 | 24.6 ± 3.12 |
| Day 14 (pre-CST) | 18.1 ± 7.02 | 15.4 ± 3.98 |
| Day 14 (post-CST) | 26.7 ± 5.56 | 22.8 ± 2.99 |
Max concentration (Cmax) of cortexolone 17α-propionate in plasma following the first application (i.e., Day 1, 0-12 hours) and last application (i.e., Day 14, 0-12 hours).
| ng/mL | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) |
|---|---|---|
| Cmax - Day 1 (ng/mL) | 3.23 ± 2.01 | 3.58 ± 4.30 |
| Cmax - Day 14 (ng/mL) | 4.46 ± 3.00 | 4.61 ± 4.74 |
Area under the plasma concentration curve (0-12 hours) of cortexolone 17α-propionate at baseline (i.e., Day 1, after first application \[0-12 hours\]) and at Day 14 (i.e., Day 14, after last application \[0-12 hours\]).
| hr*ng/mL | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) |
|---|---|---|
| AUCτ - Day 1 | 22.02 ± 13.67 | 22.55 ± 22.57 |
| AUCτ - Day 14 | 37.14 ± 22.92 | 30.97 ± 24.65 |
Average concentration of cortexolone 17α-propionate in plasma calculated as the ratio of the AUC(0-12 hours) and the dosing interval (i.e., 12 hours) at baseline (i.e., Day 1, after first application) and at Day 14 (after last application).
| ng/mL | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) |
|---|---|---|
| Cavg - Day 1 | 1.84 ± 1.14 | 1.88 ± 1.88 |
| Cavg - Day 14 | 3.10 ± 1.91 | 2.58 ± 2.05 |
Collected over 14 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cortexolone 17α-Propionate (Cohort 1) | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Cortexolone 17α-Propionate (Cohort 2) | 0/22 (0%) | 0/22 (0%) | 3/22 (13.6%) |
| Event | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) |
|---|---|---|
| ACTH stimulation test abnormalInvestigations | 1/20 | 2/22 |
| DiarrhoeaGastrointestinal disorders | 1/20 | 0/22 |
| Application site folliculitisGeneral disorders | 1/20 | 0/22 |
| Upper respiratory tract infectionInfections and infestations | 1/20 | 1/22 |
| EcchymosisSkin and subcutaneous tissue disorders | 1/20 | 0/22 |
| Ear infectionInfections and infestations | 0/20 | 1/22 |
Forty-two (42) subjects were enrolled into the study across two cohorts dependent upon age: Cohort 1: 20 adult subjects Cohort 2: 22 adolescent (12 to less than 18 years of age) subjects
| Age, Continuous(years) | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) | Total |
|---|---|---|---|
| Mean | 24.4 ± 5.84 | 15.6 ± 1.33 | 19.8 ± 6.02 |
| Sex: Female, Male(Participants) | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) | Total |
|---|---|---|---|
| Female | 15 | 12 | 27 |
| Male | 5 | 10 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 20 | 21 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cortexolone 17α-Propionate (Cohort 1) | Cortexolone 17α-Propionate (Cohort 2) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 17 | 21 | 38 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Apr 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 7 years after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Intrepid Therapeutics, Inc.